美國Seracare陽性對(duì)照品

廣州健侖生物科技有限公司

廣州健侖長期供應(yīng)各種生物原料，主要代理品牌：美國Seracare、西班牙Certest、美國Fuller等等。

主要產(chǎn)品包括各種標(biāo)準(zhǔn)品、陽性對(duì)照品、陽性質(zhì)控品、單克隆抗原抗體。

其中常見的有：弓形蟲病、西尼羅河病毒、類風(fēng)濕因子、瘧疾、麻疹、萊姆病、百日咳桿菌、大腸桿菌、鼠傷寒沙門氏菌、李斯特菌等陽性對(duì)照品。

美國Seracare陽性對(duì)照品

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

【Seracare產(chǎn)品介紹】

美國Seracare陽性對(duì)照品

在培養(yǎng)皿中，誘導(dǎo)胚胎干細(xì)胞形成視網(wǎng)膜的過程，扼要地再現(xiàn)了胚胎中眼睛發(fā)育的主要步驟。這項(xiàng)技術(shù)對(duì)基礎(chǔ)研究的價(jià)值不可估量，同時(shí)有助于開發(fā)一些療法，幫助視力減退的患者恢復(fù)視力。如下圖所示，在加入名為生長因子的分子之后，胚胎干細(xì)胞開始聚集;大約5天后，開始形成zui原始的視泡。及至第7天，視泡向外凸出;幾天后，該結(jié)構(gòu)內(nèi)陷，形成視杯;到第24天，視網(wǎng)膜的所有層次初具雛形。
應(yīng)用前景
聽說我們的研究后，人們自然想知道，用小鼠胚胎干細(xì)胞所做的工作究竟能否給眼疾患者帶來好處。在這個(gè)方向上，我們已取得了一些進(jìn)展。值得一提的是，我的實(shí)驗(yàn)室zui近剛剛在一篇文章中報(bào)道過，我們成功地使人類胚胎干細(xì)胞分化成視杯和多層神經(jīng)組織。我們預(yù)計(jì)，同樣的培養(yǎng)方法也可應(yīng)用于人類的誘導(dǎo)多能干細(xì)胞(induced pluripotent stem cells，iPS)——成熟細(xì)胞受到特定刺激后，經(jīng)過逆轉(zhuǎn)的發(fā)育過程，可成為誘導(dǎo)多能干細(xì)胞，其行為與胚胎干細(xì)胞相似。我們還發(fā)明了更好的低溫貯存方法，能在液氮中儲(chǔ)存由人類胚胎細(xì)胞分化成的視網(wǎng)膜組織。
這些工作都將推動(dòng)體外培養(yǎng)的視網(wǎng)膜組織應(yīng)用于醫(yī)學(xué)。例如，我們可以制造人工視網(wǎng)膜，幫助人們研究常見眼部疾病的病理機(jī)制，推動(dòng)新藥和基因療法的研究，逆轉(zhuǎn)視網(wǎng)膜病變。
*有數(shù)百萬人患有黃斑變性、視網(wǎng)膜色素變性(retinitis pigmentosa)和青光眼(glaucoma)，這三種視網(wǎng)膜退行性疾病的患者也許都可以從我們的研究中獲益。三種疾病中，發(fā)生病變的視網(wǎng)膜細(xì)胞層各不相同。在黃斑變性中，由于支撐組織“崩潰”，視網(wǎng)膜上皮的完整性受到影響，光感受器細(xì)胞也發(fā)生退化，尤其是視網(wǎng)膜中心區(qū)域。在視網(wǎng)膜色素變性中，視桿細(xì)胞(rod，光感受器細(xì)胞的一種)數(shù)量一年年逐漸減少，zui初也是zui常見的癥狀是“夜盲”，而后來，患者會(huì)喪失大部分視野，只剩下一小塊中心視野。在青光眼病例中，受損的則是神經(jīng)節(jié)細(xì)胞，這類細(xì)胞會(huì)伸出視神經(jīng)，把視網(wǎng)膜與大腦后部皮層上的視覺處理中心連接起來。
黃斑變性可能是這三種疾病中zui容易用細(xì)胞替代療法緩解的一種。使用傳統(tǒng)培養(yǎng)方法和我們的新方法，人類胚胎干細(xì)胞和誘導(dǎo)多能干細(xì)胞都比較容易產(chǎn)生支撐組織的細(xì)胞，即視網(wǎng)膜色素上皮細(xì)胞，并可從培養(yǎng)基中直接提取出來。美國已開始用這種細(xì)胞進(jìn)行早期小規(guī)模臨床實(shí)驗(yàn)，其他國家也有類似的實(shí)驗(yàn)計(jì)劃。在這些實(shí)驗(yàn)中，研究人員會(huì)用細(xì)針，將干細(xì)胞分化成的色素上皮細(xì)胞注射到色素上皮和光感受器細(xì)胞層之間，至少替代部分受損組織。

美國Seracare陽性對(duì)照品

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、食品安全、化妝品檢測(cè)、藥物濫用檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

The process of inducing embryonic stem cells to form the retina in petri dishes briefly reproduces the major steps in eye development in the embryo. The technology is invaluable to basic research and helps to develop therapies that help patients with vision loss regain their eyesight. As shown in the figure below, embryonic stem cells began to aggregate after the addition of a molecule called growth factor; about five days later, the most primitive vesicles began to form. By day 7, the vesicles bulged outward; a few days later, the structure retracted to form an optic cup; by day 24, all layers of the retina were initially rudimentary.
Application prospects
After hearing about our research, it is natural to wonder whether the work done with mouse embryonic stem cells can benefit patients with eye diseases. In this direction, we have made some progress. It is worth mentioning that my laboratory recently reported in an article that we successfully differentiated human embryonic stem cells into optic cups and multiple layers of neural tissue. We expect that the same culture can also be applied to human induced pluripotent stem cells (iPS), which are induced pluripotent stem cells by reversing the development of specific stimuli Embryonic stem cells are similar. We have also invented better cryogenic storage methods that store retinal tissue differentiated from human embryonic cells in liquid nitrogen.
These efforts will promote the use of cultured retinal tissue in medicine. For example, we can make artificial retina to help people study the pathological mechanism of common eye diseases, promote the research of new drugs and gene therapy, and reverse the retinopathy.
Millions of people worldwide have macular degeneration, retinitis pigmentosa and glaucoma, and all three patients with retinal degenerative diseases may benefit from our study. Of the three diseases, retinal layers of the lesion vary. In macular degeneration, the integrity of the retinal epithelium is affected by the collapsing of the supporting tissue, and the photoreceptor cells also degenerate, especially in the central retinal region. In retinitis pigmentosa, the number of rods (a type of photoreceptor cells) gradually decreases year by year, the first and most common symptom is "night blindness", and later, the patient will lose most of the field of vision, leaving only A small central field of vision. In glaucoma cases, ganglion cells are damaged, and these cells extend the optic nerve, connecting the retina to the visual processing center on the posterior cortex of the brain.
Macular degeneration may be the easiest of these three diseases to be alleviated by cell replacement therapy. Both human embryonic stem cells and induced pluripotent stem cells are more likely to produce cells that support the tissues, the retinal pigment epithelial cells, which can be extracted directly from the medium using traditional culture methods and our new approach. The United States has begun to use such cells for early small-scale clinical trials, other countries have a similar experimental plan. In these experiments, researchers injected tiny pieces of fine pigment into the pigment epithelium differentiated from stem cells between the pigment epithelium and the photoreceptor cell layer, replacing at least some of the damaged tissue.